ARCT - Arcturus Therapeutics Holdings Inc Stock Price, Fair Value and News

29.32USD-1.11 (-3.65%)Market Closed

Market Summary

USD29.32-1.11

Market Closed

-3.65%

ARCT Alerts

1 major insider sales recently.

ARCT Stock Price

View Fullscreen

ARCT RSI Chart

ARCT Valuation

Market Cap

789.2M

Price/Earnings (Trailing)

-26.55

Price/Sales (Trailing)

4.73

EV/EBITDA

-20.16

Price/Free Cashflow

-37.58

ARCT Price/Sales (Trailing)

ARCT Profitability

EBT Margin

-16.72%

Return on Equity

-10.67%

Return on Assets

-6.92%

Free Cashflow Yield

-2.66%

ARCT Fundamentals

ARCT Revenue

Revenue (TTM)

166.8M

Rev. Growth (Yr)

-80.75%

Rev. Growth (Qtr)

-31.65%

ARCT Earnings

Earnings (TTM)

-29.7M

Earnings Growth (Yr)

-109.98%

Earnings Growth (Qtr)

27.83%

Breaking Down ARCT Revenue

Last 7 days

-5.2%

Last 30 days

-19.2%

Last 90 days

-9.2%

Trailing 12 Months

6.4%

How does ARCT drawdown profile look like?

ARCT Financial Health

Current Ratio

4.72

Debt/Equity

0.07

Debt/Cashflow

-0.9

ARCT Investor Care

Shares Dilution (1Y)

0.87%

Diluted EPS (TTM)

-1.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	281.0M	264.5M	296.2M	166.8M
2022	15.5M	40.6M	51.5M	206.0M
2021	9.0M	8.7M	8.8M	12.4M
2020	19.1M	11.3M	10.3M	9.5M
2019	17.0M	18.3M	19.5M	20.8M
2018	0	0	0	15.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Arcturus Therapeutics Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	chivukula pad	sold	-610,574	35.02	-17,435	chief scientific officer & coo
Mar 19, 2024	chivukula pad	sold	-299,839	35.0075	-8,565	chief scientific officer & coo
Nov 01, 2023	chivukula pad	sold	-93,601	18.7203	-5,000	chief scientific officer & coo
Oct 02, 2023	chivukula pad	sold	-128,062	25.6123	-5,000	chief scientific officer & coo
Sep 01, 2023	chivukula pad	sold	-157,264	31.4527	-5,000	chief scientific officer & coo
Aug 15, 2023	sassine andy	acquired	21,248	17.374	1,223	chief financial officer
Aug 01, 2023	chivukula pad	sold	-174,550	34.91	-5,000	chief scientific officer & coo
Jul 14, 2023	kummerfeld keith c	sold	-243,880	35.00	-6,968	see remarks
Jul 14, 2023	kummerfeld keith c	acquired	62,408	8.95642	6,968	see remarks
Jul 14, 2023	chivukula pad	sold	-875,250	35.01	-25,000	chief scientific officer & coo

Which funds bought or sold ARCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	sold off	-100	-4,099	-	-%
Apr 10, 2024	Green Alpha Advisors, LLC	added	0.24	19,478	284,141	0.21%
Apr 05, 2024	GAMMA Investing LLC	added	10.2	208	1,824	-%
Apr 05, 2024	CWM, LLC	added	0.56	1,000	18,000	-%
Apr 01, 2024	Global Wealth Strategies & Associates	unchanged	-	224	3,377	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.66	10,037,900	45,982,700	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	140	17,320,100	26,147,300	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	68,108	365,433	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-599,000	-	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	2.29	106,000	508,000	-%

Are Funds Buying or Selling ARCT?

Are funds buying ARCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARCT

No. of Funds

ARCT Alerts

1 major insider sales recently.

Unveiling Arcturus Therapeutics Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	blackrock inc.	10.2%	2,743,002	SC 13G/A
Feb 13, 2024	vanguard group inc	5.46%	1,458,380	SC 13G/A
Feb 12, 2024	nikko asset management americas, inc.	4.94%	1,320,652	SC 13G/A
Feb 05, 2024	sumitomo mitsui trust holdings, inc.	4.94%	1,320,652	SC 13G/A
Jan 29, 2024	ark investment management llc	7.66%	2,047,687	SC 13G/A
Jan 25, 2024	blackrock inc.	9.0%	2,398,296	SC 13G/A
Jan 25, 2024	state street corp	6.10%	1,629,666	SC 13G/A
Jan 17, 2024	federated hermes, inc.	17.63%	4,711,512	SC 13G/A
Oct 10, 2023	state street corp	6.27%	1,667,925	SC 13G/A
Feb 10, 2023	nikko asset management americas, inc.	5.45%	1,449,060	SC 13G/A

Recent SEC filings of Arcturus Therapeutics Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	8-K	Current Report
Apr 05, 2024	SC 13G/A	Major Ownership Report
Mar 27, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 19, 2024	144	Notice of Insider Sale Intent
Mar 19, 2024	8-K	Current Report
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	8-K/A	Current Report
Mar 07, 2024	8-K	Current Report
Feb 23, 2024	8-K	Current Report

Peers (Alternatives to Arcturus Therapeutics Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Arcturus Therapeutics Holdings Inc News

Latest updates

Arcturus Therapeutics Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-31.6%	30,855,000	45,140,000	10,519,000	80,285,000	160,293,000	13,369,000	27,093,000	5,244,000	5,794,000	2,437,000	2,001,000	2,127,000	2,238,000	2,333,000	2,322,000	2,646,000	2,968,000	3,318,000	10,153,000	4,350,000	3,886,500
Operating Expenses	-23.8%	49,127,000	64,454,000	65,893,000	65,530,000	38,841,000	50,176,000	49,182,000	55,623,000	43,439,000	56,258,000	55,721,000	59,793,000	33,320,000	23,271,000	12,364,000	12,108,000	13,785,000	10,934,000	10,725,000	10,858,000	-
S&GA Expenses	-6.5%	12,507,000	13,377,000	13,225,000	13,762,000	11,860,000	12,488,000	10,993,000	10,730,000	10,806,000	10,860,000	10,042,000	9,743,000	9,034,000	5,572,000	4,420,000	4,191,000	1,791,000	3,881,000	3,456,000	3,534,000	-
R&D Expenses	-28.3%	36,620,000	51,077,000	52,668,000	51,768,000	26,981,000	37,688,000	38,189,000	44,893,000	32,633,000	45,398,000	45,679,000	50,050,000	24,286,000	17,699,000	7,944,000	7,917,000	11,994,000	7,053,000	7,269,000	7,324,000	-
EBITDA Margin	-137.8%	-0.14	0.36	0.33	0.42	0.06	-3.91	-4.97	-13.05	-16.33	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	25,000	-	-	2,102,000	228,000	230,000	186,000	169,000	170,000	173,000	172,000	169,000	578,000	-7,000	-48,000	228,000	183,000	168,000	173,000	167,000	-
Income Taxes	-72.6%	247,000	900,000	600,000	103,000	-	-	-	100,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	25.3%	-11,445,000	-15,329,000	-51,973,000	50,857,000	118,642,000	-35,266,000	-21,563,000	-51,169,000	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-148.5%	-0.17	0.34	0.31	0.40	0.05	-3.95	-5.02	-13.16	-16.48	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	27.8%	-11,707,000	-16,222,000	-52,550,000	50,754,000	117,347,000	-35,266,000	-21,563,000	-51,169,000	-38,663,000	-54,084,000	-54,581,000	-56,346,000	-31,104,000	-21,004,000	-10,263,000	-9,777,000	-10,989,000	-7,433,000	-685,000	-6,884,000	-
Net Income Margin	-153.1%	-0.18	0.34	0.30	0.40	0.05	-2.85	-4.08	-12.83	-16.48	-22.28	-18.74	-13.16	-	-	-	-	-	-	-	-	-
Free Cashflow	95.5%	-1,504,000	-33,387,000	50,453,000	-36,562,000	156,452,000	-44,592,000	-36,443,000	-51,150,000	-43,615,000	-18,419,000	-33,347,000	-43,068,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-6.2%	429	458	431	471	450	294	337	342	393	435	449	481	476	323	150	72.00	82.00	87.00	71.00	44.00
Current Assets	-1.7%	387	393	385	425	403	247	292	327	379	421	438	470	468	314	142	64.00	74.00	79.00	63.00	42.00
Cash Equivalents	11.9%	349	312	323	328	392	238	283	320	373	414	434	467	463	307	136	59.00	71.00	74.00	56.00	37.00
Net PPE	-2.3%	12.00	13.00	13.00	13.00	12.00	11.00	9.00	8.00	6.00	5.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00
Liabilities	-15.0%	151	178	145	142	180	148	166	157	165	175	143	129	80.00	61.00	57.00	55.00	56.00	51.00	49.00	31.00
Current Liabilities	-6.5%	82.00	88.00	90.00	90.00	127	76.00	93.00	107	100	118	71.00	53.00	50.00	28.00	23.00	22.00	21.00	22.00	16.00	13.00
Long Term Debt	-100.0%	-	20.00	-	-	-	32.00	36.00	39.00	41.00	42.00	56.00	58.00	14.00	15.00	15.00	15.00	15.00	10.00	10.00	10.00
LT Debt, Current	-	-	-	-	-	61.00	28.00	27.00	24.00	22.00	-	-	-	1.00	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	20.00	-	-	-	32.00	36.00	39.00	41.00	42.00	56.00	58.00	14.00	15.00	15.00	15.00	15.00	10.00	10.00	10.00
Shareholder's Equity	-0.6%	279	280	285	329	270	146	171	185	228	259	306	353	397	262	93.00	17.00	26.00	36.00	22.00	14.00
Retained Earnings	-3.3%	-367	-356	-339	-287	-338	-455	-420	-398	-347	-308	-254	-200	-143	-112	-91.71	-81.44	-71.70	-60.68	-53.25	-44.87
Additional Paid-In Capital	1.6%	646	636	625	617	608	601	591	583	576	568	560	553	540	374	185	98.00	97.00	97.00	75.00	58.00
Shares Outstanding	0.4%	27.00	27.00	27.00	27.00	27.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	376	-	-	-	700	-	-	-	701	-	-	-	76.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	98.1%	-629	-32,406	50,807	-35,871	160,259	-42,406	-36,821	-49,039	-42,497	-16,653	-32,943	-42,950	-6,632	-15,877	-8,494	-11,858	-7,538	-2,836	9,340	-5,411	-
Share Based Compensation	-4.9%	8,815	9,269	8,383	8,182	6,530	9,436	7,274	7,371	7,518	6,870	7,540	6,987	2,826	1,988	1,101	849	797	383	403	399	-
Cashflow From Investing	10.8%	-875	-981	-354	-691	-3,807	-2,186	378	-2,111	-1,118	-1,766	-404	-118	-697	-434	-469	-142	-315	-159	-266	-78.00	-
Cashflow From Financing	-185.4%	-18,657	21,840	94.00	-27,364	-2,232	-1,220	257	336	230	692	82.00	47,012	163,201	187,223	85,603	118	5,034	21,327	-	-	-

ARCT Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 166,799	$ 205,999	$ 12,359
Operating expenses:
Research and development, net	192,133	147,751	173,760
General and administrative	52,871	46,071	41,451
Total operating expenses	245,004	193,822	215,211
(Loss) income from operations	(78,205)	12,177	(202,852)
(Loss) gain from equity-method investment		(515)	515
(Loss) gain from foreign currency	(229)	(598)	584
Finance income (expense), net	16,591	(420)	(1,921)
Gain on debt extinguishment	33,953
Net (loss) income before income taxes	(27,890)	10,644	(203,674)
Provision for income taxes	1,835	1,295
Net (loss) income	$ (29,725)	$ 9,349	$ (203,674)
(Loss) earnings per share:
Basic	$ (1.12)	$ 0.35	$ (7.74)
Diluted	$ (1.12)	$ 0.35	$ (7.74)
Weighted-average shares used in calculation of (loss) earnings per share:
Basic	26,628	26,445	26,317
Diluted	26,628	27,093	26,317
Comprehensive (loss) income:
Net (loss) income	$ (29,725)	$ 9,349	$ (203,674)
Comprehensive (loss) income	(29,725)	9,349	(203,674)
Collaboration Revenue [Member]
Revenue:
Total revenue	157,748	205,755	$ 12,359
Grant Revenue [Member]
Revenue:
Total revenue	$ 9,051	$ 244

ARCT Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 292,005	$ 391,883
Restricted cash	55,000
Accounts receivable	32,064	2,764
Prepaid expenses and other current assets	7,521	8,686
Total current assets	386,590	403,333
Property and equipment, net	12,427	12,415
Operating lease right-of-use asset, net	28,500	32,545
Non-current restricted cash	1,885	2,094
Total assets	429,402	450,387
Current liabilities:
Accounts payable	5,279	7,449
Accrued liabilities	31,881	30,232
Current portion of long-term debt		60,655
Deferred revenue	44,829	28,648
Total current liabilities	81,989	126,984
Deferred revenue, net of current portion	42,496	20,071
Operating lease liability, net of current portion	25,907	30,216
Other non-current liabilities	497	2,804
Total liabilities	150,889	180,075
Stockholders’ equity:
Common stock: $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,828 at December 31, 2023 and 26,555 at December 31, 2022	27	27
Additional paid-in capital	646,352	608,426
Accumulated deficit	(367,866)	(338,141)
Total stockholders’ equity	278,513	270,312
Total liabilities and stockholders’ equity	$ 429,402	$ 450,387

About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.

CEO	Mr. Joseph E. Payne M.Sc.
WEBSITE	https://arcturusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	170

Arcturus Therapeutics Holdings Inc Frequently Asked Questions

What is the ticker symbol for Arcturus Therapeutics Holdings Inc? What does ARCT stand for in stocks?

ARCT is the stock ticker symbol of Arcturus Therapeutics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcturus Therapeutics Holdings Inc (ARCT)?

As of Mon Apr 15 2024, market cap of Arcturus Therapeutics Holdings Inc is 789.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARCT stock?

You can check ARCT's fair value in chart for subscribers.

What is the fair value of ARCT stock?

You can check ARCT's fair value in chart for subscribers. The fair value of Arcturus Therapeutics Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcturus Therapeutics Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcturus Therapeutics Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ARCT is over valued or under valued. Whether Arcturus Therapeutics Holdings Inc is cheap or expensive depends on the assumptions which impact Arcturus Therapeutics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARCT.

What is Arcturus Therapeutics Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, ARCT's PE ratio (Price to Earnings) is -26.55 and Price to Sales (PS) ratio is 4.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Arcturus Therapeutics Holdings Inc's stock?

In the past 10 years, Arcturus Therapeutics Holdings Inc has provided -0.123 (multiply by 100 for percentage) rate of return.